
    
      The investigator's project is a single medical center, randomized double- blinded trial. The
      target group is terminal cancer patients at Palliative care clinics. The experimental group
      will receive intravenous high-dose vitamin C 30 g in 500 ml normal saline in 1-hour infusion,
      once per week, and total 4-week treatment. The control group will receive 500 ml normal
      saline in 1-hour infusion, once per week, and total 4-week treatment. The primary outcome is
      the improvement of quality of life, measured by European Organization for Research and
      Treatment of cancer (EORTC). The secondary outcome is the survival analysis.The participants
      will be followed up weekly for 2 weeks, then bi-weekly for 6 months.
    
  